# Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ

> **NCT00555152** · NA · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 22 (actual)

## Conditions studied

- Ductal Breast Carcinoma In Situ
- HER2/Neu Positive

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lapatinib Ditosylate
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00555152
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-19
- **Primary completion:** 2014-08-28
- **Final completion:** 2014-08-28
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2018-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00555152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00555152, "Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00555152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*